![]() |
Name |
Tricycloalternarene 2a
|
Molecular Formula | C21H30O4 | |
IUPAC Name* |
5-hydroxy-1-[(E)-7-hydroxy-6-methylhept-5-en-2-yl]-3a-methyl-3,5,6,7,9,9a-hexahydrocyclopenta[b]chromen-8-one
|
|
SMILES |
CC(CC/C=C(\C)/CO)C1=CCC2(C1CC3=C(O2)C(CCC3=O)O)C
|
|
InChI |
InChI=1S/C21H30O4/c1-13(12-22)5-4-6-14(2)15-9-10-21(3)17(15)11-16-18(23)7-8-19(24)20(16)25-21/h5,9,14,17,19,22,24H,4,6-8,10-12H2,1-3H3/b13-5+
|
|
InChIKey |
BDMIMSPBTFWTBC-WLRTZDKTSA-N
|
|
Synonyms |
Tricycloalternarene 2a; 103873-60-5; 3,3a,6,7,9,9a-hexahydro-5-hydroxy-1[(e)-7-hydroxy-6-methylhept-5-en-2-yl]-3a-methylcyclopenta[b]chromen-8(5h)-one; Cyclopenta(b)(1)benzopyran-8(3H)-one, 3a,5,6,7,9,9a-hexahydro-5-hydroxy-1-(6-hydroxy-1,5-dimethyl-4-hexenyl)-3a-methyl-
|
|
CAS | 103873-60-5 | |
PubChem CID | 6443494 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 346.5 | ALogp: | 2.1 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 3 |
Heavy Atoms: | 25 | QED Weighted: | 0.733 |
Caco-2 Permeability: | -4.508 | MDCK Permeability: | 0.00002150 |
Pgp-inhibitor: | 0.023 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.149 | 20% Bioavailability (F20%): | 0.907 |
30% Bioavailability (F30%): | 0.023 |
Blood-Brain-Barrier Penetration (BBB): | 0.785 | Plasma Protein Binding (PPB): | 78.92% |
Volume Distribution (VD): | 1.333 | Fu: | 10.99% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.195 |
CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.581 |
CYP2C9-inhibitor: | 0.023 | CYP2C9-substrate: | 0.221 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.594 |
CYP3A4-inhibitor: | 0.435 | CYP3A4-substrate: | 0.261 |
Clearance (CL): | 15.152 | Half-life (T1/2): | 0.637 |
hERG Blockers: | 0.003 | Human Hepatotoxicity (H-HT): | 0.323 |
Drug-inuced Liver Injury (DILI): | 0.317 | AMES Toxicity: | 0.008 |
Rat Oral Acute Toxicity: | 0.576 | Maximum Recommended Daily Dose: | 0.527 |
Skin Sensitization: | 0.042 | Carcinogencity: | 0.882 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.026 |
Respiratory Toxicity: | 0.714 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001868 | ![]() |
0.792 | D0T2PL | ![]() |
0.238 | ||
ENC005805 | ![]() |
0.792 | D04VIS | ![]() |
0.234 | ||
ENC005807 | ![]() |
0.792 | D02VPX | ![]() |
0.231 | ||
ENC003211 | ![]() |
0.704 | D08SVH | ![]() |
0.228 | ||
ENC003123 | ![]() |
0.655 | D0K5WS | ![]() |
0.225 | ||
ENC005806 | ![]() |
0.628 | D0L7AS | ![]() |
0.222 | ||
ENC004443 | ![]() |
0.624 | D04ATM | ![]() |
0.221 | ||
ENC003212 | ![]() |
0.551 | D0Y7IU | ![]() |
0.220 | ||
ENC003124 | ![]() |
0.511 | D04QNO | ![]() |
0.220 | ||
ENC003577 | ![]() |
0.505 | D05BTM | ![]() |
0.218 |